🇺🇸 FDA

Company profile · Sponsor

KAZIA

KAZIA THERAPEUTICS LTD

KZIA · NYSE pharma SYDNEY NSW, USA
Pipeline
13
Drugs
0
Patents
1

Quick answer

KAZIA (KZIA) is a pharma company. headquartered in SYDNEY NSW, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 1 patent to this profile..

Company facts

Ticker KZIA
Exchange NYSE
Company type pharma
Headquarters SYDNEY NSW, USA
SEC CIK 0001075880

Pipeline (13)

Search pipeline →

  1. Abemaciclib

    KAZIA

    CDK Gene Mutation

    phase 2 small molecule active

    1 trial

  2. PAXALISIB

    KAZIA

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  3. Paxalisib

    KAZIA

    Malignant Primary Gliomas

    phase 2 small molecule active

    1 trial

  4. Paxalisib

    KAZIA

    Childhood Cancer

    phase 2 small molecule active

    1 trial

  5. Paxalisib

    KAZIA

    Glioblastoma

    phase 2 small molecule on hold

    1 trial

  6. Paxalisib (GDC-0084)

    KAZIA

    Glioblastoma, Adult

    phase 2 small molecule completed

    1 trial

  7. Trastuzumab

    KAZIA

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  8. EVT801

    KAZIA

    Solid Tumor, Adult

    phase 1 small molecule completed

    1 trial

  9. GDC-0084

    KAZIA

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  10. GDC-0084

    KAZIA

    Brain Metastases

    phase 1 small molecule active

    1 trial

  11. Part A: Dose Escalation of Cantrixil

    KAZIA

    Ovarian Neoplasms

    phase 1 small molecule completed

    1 trial

  12. [14C]-Paxalisib Capsule

    KAZIA

    Healthy

    phase 1 small molecule completed

    1 trial

  13. idronoxil

    KAZIA

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 1 small molecule completed

    1 trial

Patents (1)

Search patents →

  1. US 10370349

    Functionalised benzopyran compounds and use thereof

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is KAZIA?

KAZIA (KZIA) is a pharma company. headquartered in SYDNEY NSW, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 1 patent to this profile..

What pipeline programs does KAZIA sponsor?

We track 13 ClinicalTrials.gov-linked programs for KAZIA, including Abemaciclib and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does KAZIA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.